Abstracts Archive - Page 858 of 2425 - ACR Meeting Abstracts

Abstract Number: 1494 • 2019 ACR/ARP Annual Meeting
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Joseph Merola¹, Shu Li ², Ming-Chun Hsu ², Chetan Karyekar ³, Susan Flavin ², Bruce Randazzo ⁴ and Laura Coates ⁵, ¹Brigham and Women's Hospital, Harvard Med School, Boston, MA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to…
Abstract Number: 1495 • 2019 ACR/ARP Annual Meeting
Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients
Guy Baudens ¹, Pascal Coquerelle ², Marie-Helene Guyot ³, Sylvie Loiseau-Pères ⁴, Laurent Marguerie ⁵, Frédéric Maury ⁶, Viellard Eric ⁷, Jean-Guillaume Letarouilly ⁸, Jean-Hugues Salmon ⁹, René-Marc Flipo ⁸ and Elisabeth Gervais¹⁰, ¹Rheumatology, Private practice, Valenciennes, France, ²Rheumatology, Bethune Hospital, France, France, ³Rheumatology, Roubaix Hospital, Roubaix, France, ⁴Rheumatology, Orléans Hospital, Orléans, France, ⁵Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ⁶Rheumatology, Private Practice, Beuvry, Beuvry, France, ⁷Rheumatology, Private practice, Saint Malo, France, ⁸Roger Salengro University-Hospital, Lille , France, Lille, France, ⁹Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁰CHU de Poitiers, Rheumatology, Poitiers, France
Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate…
Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
Josef Smolen¹, Panagiotis Athanassiou ², Paul Bergmans ³, Irina Bondareva ⁴, Kurt De Vlam ⁵, Elisa Gremese ⁶, Beatriz Joven-Ibáñez ⁷, Tatiana Korotaeva ⁸, Wim Noël ⁹, Michael Nurmohamed ¹⁰, Petros Sfikakis ¹¹, Stefan Siebert ¹², Pavel Smirnov ¹³, Elke Theander ¹⁴ and Laure Gossec ¹⁵, ¹Medical University of Vienna, Vienna, Austria, ²General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴GUZ Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁹Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ¹⁰Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹¹Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ¹³Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹⁴Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹⁵Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…
Abstract Number: 1497 • 2019 ACR/ARP Annual Meeting
Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Alan Kivitz¹, Joel Kremer ², Clarence Legerton ³, Jacqueline Palmer ⁴, Xiangyi Meng ⁴, Luminita Pricop ⁴ and Atul Singhal ⁵, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Albany Medical College, Albany, NY, ³Low Country Rheumatology/Articularis Healthcare, North Charleston, SC, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Southwest Rheumatology, Dallas, TX
Background/Purpose: Secukinumab (SEC), a selective inhibitor of interleukin 17A, demonstrated rapid, significant, and sustained improvement in the signs and symptoms of PsA, with a favorable…
Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Tien Nguyen¹, Melvin Churchill ², Robert Levin ³, Guillermo Valenzuela ⁴, Joseph Merola ⁵, Alexis Ogdie ⁶, Ana-Maria Orbai ⁷, Jose Scher ⁸, Arthur Kavanaugh ⁹, Shital Agawane ¹⁰, Farid Kianifard ¹¹, Chauncy Rollins ¹¹ and Olivier Chambenoit ¹¹, ¹Department of Dermatology, University of California, Irvine, Irvine, CA, ²Arthritis Center of Nebraska, Lincoln, NE, ³Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁹University of California, San Diego School of Medicine, La Jolla, CA, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
René-Marc Flipo ¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Jean-Marie Fayette ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Fernando Pimentel-Santos ¹, Nélia Gouveia ³, Anabela Barcelos ⁴, Jaime Branco ¹, Miguel Bernardes ⁵, Raquel Miriam-Ferreira ⁵, Elsa Vieira-Sousa ⁶, Sofia Barreira ⁶, Filipe Vinagre ⁷, Raquel Roque ⁷, Helena Santos ⁸, Nathalie Madeira ⁸, João Rovisco ⁹, Alexandra Daniel ⁹ and Sofia Ramiro ¹⁰, ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, ⁴Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ⁷Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁸Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, ¹⁰Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
Abstract Number: 1501 • 2019 ACR/ARP Annual Meeting
Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Maxime Dougados¹, Joachim Sieper ², Xenofon Baraliakos ³, Filip Van den Bosch ⁴, Walter P. Maksymowych ⁵, Joerg Ermann ⁶, Xiaoqi Li ⁷, Gaia Gallo ⁸, Hilde Carlier ⁷ and Lianne Gensler ⁹, ¹Hôpital Cochin, Paris, France, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Brigham and Women's Hospital, Boston, ⁷Eli Lilly and Company, Indianapolis, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹University San Francisco California, San Francisco, CA
Background/Purpose: Week 16 results from COAST-W (NCT02696798) showed that ixekizumab (IXE) was superior to placebo (PBO) in improving the signs and symptoms of active radiographic…
Abstract Number: 1502 • 2019 ACR/ARP Annual Meeting
The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Maxime Dougados¹, Désirée van der Heijde ², Clifton Bingham ³, Peter Taylor ⁴, Lara Fallon ⁵, John Woolcott ⁶, Yves Brault ⁷, Lisy Wang ⁸ and Meriem Kessouri ⁷, ¹Cochin Hospital, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Johns Hopkins University, Baltimore, MD, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Paris, France, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Current treatments for PsA have proven effective in reducing patient (pt)-reported pain;1,2 however, residual pain often remains. Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 1503 • 2019 ACR/ARP Annual Meeting
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Mark Genovese¹, Hideto Kameda ², Proton Rahman ³, Juan Cañete ⁴, Sandra Garces ⁵, Wen Xu ⁶, Matthew M. Hufford ⁵ and Bernard Combe ⁷, ¹Stanford University, Stanford, CA, ²Toho University, Tokyo, Japan, Tokyo, Japan, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that specifically targets IL-17A. Pooled safety data from IXE studies in moderate-to-severe plaque psoriasis (PsO) and psoriatic…
Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Helena Marzo-Ortega¹, Corinne Miceli-Richard ², Sonja Gill ³, Marina Magrey ⁴, Paula Machado ⁵, Abhijit Shete ⁶, Jianyuan Wang ⁶, Susanne Rohrer ⁶ and Atul Deodhar ⁷, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
Abstract Number: 1505 • 2019 ACR/ARP Annual Meeting
Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Xenofon Baraliakos¹, Denis Poddubnyy ², Frank Behrens ³, Cinzia Curiale ⁴, Miriam Tarallo ⁴, Ana Cristina Hernandez Daly ⁵, Olaf Behmer ⁶, Joseph Cappelleri ⁷, Nicholas Hudson ⁸ and Christen Gray ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ³Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Pfizer Inc., Rome, Italy, ⁵Pfizer Inc., Athens, Greece, ⁶Pfizer Inc., Berlin, Germany, ⁷Pfizer Inc, Groton, CT, ⁸IQVIA, London, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treatment includes biologics, prescribed on a long-term basis. As persistence data from real-world practice are limited, the…
Abstract Number: 1506 • 2019 ACR/ARP Annual Meeting
Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results
Xenofon Baraliakos¹, Sebastian Kruse ², Simone Auteri ³, Natasha de Peyrecave ⁴, Tommi Nurminen ⁵, Thomas Kumke ⁵, Bengt Hoepken ⁶ and Jürgen Braun ², ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Monheim am Rhein, Germany
Background/Purpose: Inflammation of the spine is believed to trigger a repair mechanism that results in syndesmophyte formation in axial spondyloarthritis (axSpA) patients (pts).1 Bone marrow…
Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Lianne Gensler ², Jonathan Kay ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Robert B.M. Landewé ⁶, Martin Rudwaleit ⁷, Stephen Hall ⁸, Lars Bauer ⁹, Bengt Hoepken ⁹, Natasha de Peyrecave ¹⁰, Thomas Kumke ¹¹ and Désirée van der Heijde ¹², ¹Oregon Health & Science University, Portland, OR, ²University San Francisco California, San Francisco, CA, ³UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁸Monash University and Emeritus Research, Melbourne, Australia, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹UCB Pharma, Monheim, Germany, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…
Abstract Number: 1508 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler ¹, Jonathan Kay ², Walter P. Maksymowych ³, Nigil Haroon ⁴, Lars Bauer ⁵, Bengt Hoepken ⁵, Natasha de Peyrecave ⁶, Thomas Kumke ⁷ and Atul Deodhar⁸, ¹University San Francisco California, San Francisco, CA, ²UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].